Navigation Links
CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Date:1/16/2008

of CeNeRx's Tyrima should enable patients to benefit from the efficacy advantages of the class while avoiding the food- associated cardiovascular side effects of older MAOIs. The potential for these adverse effects has greatly restricted the use of conventional MAOI agents.

The Phase l program evaluated a range of Tyrima doses in 65 subjects. The repeat dose study results confirmed the positive findings of the acute dose trial that were reported previously. Tyrima was well tolerated, with no clinically significant adverse events reported at any dose. It achieved high plasma concentrations and exhibited a favorable pharmacokinetic half-life consistent with once- or twice-daily dosing.

"Successful completion of the Phase l program is a major milestone for our third-generation RIMA agents, whose triple-action mechanism has the potential to provide greater antidepressant efficacy to the many patients who do not obtain adequate relief from currently available therapies," said Barry Brand, chief executive officer of CeNeRx. "Tyrima offers a mechanism of action that is well-precedented and it has novel safety advantages. We look forward to rapidly advancing the Phase ll program."

CeNeRx has worldwide rights to develop and commercialize Tyrima. This compound, which could be the first RIMA antidepressant available in the U.S. market, has patent protection beyond 2027.

About CeNeRx BioPharma

CeNeRx (SEN-er-ex) is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, has completed Phase I development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its preclinical pipeline of selective cannabinoid compounds for
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
2. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
5. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
6. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Atlanta, GA (PRWEB) August 30, 2014 ... US Open Challenge and K.Warrior Search on November 8th, ... Over 20 years, these events have introduced many notorious ... such as Strike-Force, IWF and the UFC. , ... seen numerous fighters leave its doors armed with the ...
(Date:8/30/2014)... 30 August 2014: The first multidisciplinary recommendations on ... coronary syndromes (ACS) are published today in ... written jointly by the European Heart Rhythm Association ... the European Association of Percutaneous Cardiovascular Interventions (EAPCI), ... Gorenek (Turkey), chairperson of the task force, said: ...
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations on ... pulmonary embolism are published today in new ESC ... by Professor Stavros V. Konstantinides (Germany/Greece) and Professor ... on the diagnosis and management of acute pulmonary ... Journal (1) and on the ESC Website. , ...
(Date:8/29/2014)... Daily Gossip writes in its review that this is ... This method promises to teach readers how to eliminate the ... alternative sources for the production of energy. , Some ... solar power. , The Home Made Energy review indicates ... So, this is an online guide that will teach its ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Cancer ... loved ones and caretakers. Author Eddie M. Leung knows the ... cholangiocarcinoma or bile duct cancer, a very rare and ... That Changed My Life” (published by Xlibris), he shares a ... importantly, he imparts a survivor’s testimony that this disease can ...
Breaking Medicine News(10 mins):Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3
... may not be at,the top of your list of fun ... makes having any kind of fun a lot harder in ... your fiber intake, while enjoying the,benefits of regularity., Listen ... http://media.medialink.com/WebNR.aspx?story=35262 ., Registered journalists can access video, audio, text, ...
... Ind., June 19 Zimmer Holdings, Inc.,(NYSE: ... that it will partner with AmeriCares,one of ... donations, to support emergency response and ongoing ... at $1 million to,three of AmeriCares, primary ...
... a major international clinical trial coordinated by the Montreal ... England Journal of Medicine . The Atrial Fibrillation and ... project involving patients with heart failure and atrial fibrillation. ... the population and associated atrial fibrillation (a very common ...
... for diarrhea worldwide, study says , , THURSDAY, June 19 (HealthDay ... may help dysentery-causing amoeba evade the immune system. , ... fight dysentery, a form of diarrhea that affects about 500 ... threat in many regions. , "This is the first ...
... June 19 NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ... and hospitals throughout the United States,today announced the final ... at 5:00 p.m. Eastern Time on Friday, June 13, ... depositary for the tender offer, an,aggregate of 2,240,883 shares ...
... June 19 Minneapolis-based Courage Center,is pleased to announce ... 2008,Eleven Who Care Agency of Distinction., Over the ... has,recognized the outstanding efforts of 264 (275 including 2008) ... amazing. Since the,awards began, 12 Courage Center volunteers (including ...
Cached Medicine News:Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 2Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 3Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3Health News:Scientists ID Enzyme That Allows Dysentery Amoeba to Hide 2Health News:NightHawk Radiology Holdings, Inc. Announces Final Results of Tender Offer; NightHawk Purchases 2,240,883 Shares of Its Common Stock at $8.05 per Share 2Health News:Courage Center Honored With KARE TV's 2008 Eleven Who Care Agency of Distinction 2
... with brass and aluminum body., ... suffix S to model number. Example: ... suffix C to model number. Example: ... Power Take-Off, add PT to model ...
... FM Series Oxygen Flowmeters with Power ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... proficiency testing solutions with outstanding customer service ... is one of the largest proficiency testing ... laboratories enrolled. Here are just some of ... Paperless Proficiency Testing, Free CME/CMLE Credits ...
... a new functional test which exhibits 100% ... C Resistance caused by the Factor V ... commercially available methods, Pefakit APC-R FVL shows ... Lupus Anticoagulants, Elevated FVIII levels, Heparins or ...
Medicine Products: